TP53 and neoplasm: The significantly reduced sarcoma latency in double-mutant Dmd −/−Dysf−/−- and Dmd −/−Capn3 −/− mice also resembles a common feature of tumor suppressor mouse models, as exemplified by the synergistic effect of a combined loss of p53 and Nf1, which accelerates soft-tissue sarcoma development [24].